KD Logo

Taking a Closer Look At Revance Therapeutics Inc (RVNC) Following Its Recent Trade

Revance Therapeutics Inc’s recent filing unveils that its Chief Commercial Officer Jordan Erica unloaded Company’s shares for reported $9096.0 on Apr 16 ’24. In the deal valued at $3.80 per share,2,392 shares were sold. As a result of this transaction, Jordan Erica now holds 114,864 shares worth roughly $0.6 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Sjuts Dustin S sold 9,211 shares, generating $46,446 in total proceeds. Upon selling the shares at $5.04, the President now owns 167,550 shares.

Before that, Moxie Dwight sold 8,125 shares. Revance Therapeutics Inc shares valued at $40,971 were divested by the CLO & GC at a price of $5.04 per share. As a result of the transaction, Moxie Dwight now holds 137,815 shares, worth roughly $0.72 million.

Mizuho downgraded its Revance Therapeutics Inc [RVNC] rating to a Neutral from a a Buy in a research note published on January 29, 2024; the price target was decreased to $9 from $16. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Exane BNP Paribas also remained covering RVNC and has increased its forecast on August 16, 2023 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley started covering the stock on October 11, 2022. It rated RVNC as “an Equal-weight”.

Price Performance Review of RVNC

On Tuesday, Revance Therapeutics Inc [NASDAQ:RVNC] saw its stock jump 1.17% to $5.20. Over the last five days, the stock has lost -0.38%. Revance Therapeutics Inc shares have fallen nearly -40.84% since the year began. Nevertheless, the stocks have fallen -39.81% over the past one year. While a 52-week high of $9.90 was reached on 01/02/24, a 52-week low of $2.30 was recorded on 06/26/24. SMA at 50 days reached $5.79, while 200 days put it at $4.80.

Levels Of Support And Resistance For RVNC Stock

The 24-hour chart illustrates a support level at 5.09, which if violated will result in even more drops to 4.99. On the upside, there is a resistance level at 5.29. A further resistance level may holdings at 5.38. The Relative Strength Index (RSI) on the 14-day chart is 38.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.00%. Stochastics %K at 35.23% indicates the stock is a holding.

How much short interest is there in Revance Therapeutics Inc?

A steep rise in short interest was recorded in Revance Therapeutics Inc stocks on 2024-09-30, growing by 1.98 million shares to a total of 9.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 7.56 million shares. There was a rise of 20.79%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on September 22, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $33 price target.

Most Popular